Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9818617 | 0.93 | HDAC4 (0.49) | ADRA1DADRA1AADRA1BHDAC4BDKRB1 | |
| SCHEMBL625570 | 0.93 | HDAC4 (0.45) | ADRA1DADRA1AADRA1BHDAC4BDKRB1 | |
| SCHEMBL5726943 | 0.89 | ADRA1D (0.41) | ADRA1DADRA1AADRA1BHDAC4BDKRB1 | |
| SCHEMBL23778356 | 0.87 | ADRA1D (0.42) | ADRA1DADRA1AADRA1BHDAC4BDKRB1 | |
| Hydrochloric Acid SCHEMBL4816093 | 0.87 | HTR2C (0.42) | ADRA1DADRA1AADRA1BHDAC4BDKRB1 | |
| SCHEMBL5075856 | 0.84 | PDE7A (0.35) | ADRA1DADRA1AADRA1BHDAC4BDKRB1 | |
| SCHEMBL30017996 | 0.83 | ADRA1D (0.47) | ADRA1DADRA1AADRA1BHDAC4BDKRB1 | |
| SCHEMBL23270127 | 0.83 | HDAC4 (0.45) | ADRA1DADRA1AADRA1BHDAC4BDKRB1 | |
| SCHEMBL16729399 | 0.83 | HDAC6 (0.38) | ADRA1DADRA1AADRA1BHDAC4BDKRB1 | |
| SCHEMBL6888519 | 0.82 | ADRA1D (0.53) | ADRA1DADRA1AADRA1BBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021078995-A1 | SELECTIVE POLYPEPTIDE SYNTHESIS STALLING ASSAY AND COMPOUND | UMC UTRECHT HOLDING B.V. (NL) | 2021-04-29 | — | — | WO | disclosed |
| EP-3811945-A1 | COMPOUNDS FOR TREATING AND PREVENTING GROWTH HORMONE RECEPTOR-DEPENDENT CONDITIONS | UMC Utrecht Holding B.V. (NL) | 2021-04-28 | — | — | EP | disclosed |
| EP-3191449-B1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-07-01 | — | — | EP | disclosed |
| EP-3191449-B1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-07-01 | — | — | EP | disclosed |
| CN-107250110-B | Novel compounds as inhibitors of transfection Rearrangement (RET) | 葛兰素史克知识产权发展有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-9879021-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-30 | — | — | US | disclosed |
| US-9879021-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-30 | — | — | US | disclosed |
| US-9879021-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-30 | — | — | US | disclosed |
| US-20170298074-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298074-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298074-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-19 | — | — | US | disclosed |
| EP-2134692-A2 | QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION | Wyeth a Corporation of the State of Delaware (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008121817-A2 | QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION | WYETH (US) | 2008-10-09 | — | — | WO | disclosed |
| US-4859232-A | Substituted-aryl cyclopropanecarbonitriles and derivatives thereof as herbicide antidotes | MONSANTO COMPANY (US) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | RET, FER, THRB | ADRA1D 3055/4885ADRA1A 3641/4885ADRA1B 3357/4885 |
| US-20170298074-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | ADRA1D 3250/4885ADRA1A 3842/4885ADRA1B 3612/4885 |
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | VCAM1, ICAM1, SELE | ADRA1D 1029/4885ADRA1A 898/4885ADRA1B 1123/4885 |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | ADRA1D 3250/4885ADRA1A 3842/4885ADRA1B 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.